Long-Term Follow-up of Tandem High-Dose Therapy With Peripheral Blood Stem Cell for Adults With High-Risk Age-Adjusted IPI Aggressive Non-Hodgkin's Lymphomas (073)

French Innovative Leukemia Organisation

Status and phase: Completed; Phase 2

Conditions: Lymphoma

Treatments: Procedure: Tandem high-dose therapy (HDT) followed by autologous peripheral blood stem cell (PBSC); Drug: CEEP regimen

Study type: Interventional

Funder types: Other; Industry

Identifiers

NCT00869284

GOELAMS 073

no other identification number

Details and patient eligibility

About

Phase II multicenter pilot trial (073) evaluating tandem HDT with PBSC support in aa-IPI=3 untreated aggressive NHL.

Full description

High-dose chemotherapy; untreated aggressive non-Hodgkin's lymphoma; high-risk; peripheral blood stem cell support Patients were aged from 15 to 60 years

Enrollment: 45 patients

Sex: All

Ages: 15 to 60 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• patients aged from 15 to 60 years
• previously untreated
• histologically proven aggressive NHL
• high aa-IPI (equal to 3)
• proper underlying organ function

Exclusion criteria

• transformed low-grade, lymphoblastic, mantle-cell, or Burkitt's lymphoma

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)